Literature DB >> 12606741

Suppressing hepatitis B without resistance--so far, so good.

Mark E Mailliard, John L Gollan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12606741     DOI： 10.1056/NEJMe020185

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Adefovir dipivoxil: a review of its use in chronic hepatitis B.

Authors:  Toni Dando; Greg Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Drugs in development for hepatitis B.

Authors:  Maria Buti; Rafael Esteban
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Prevalence of HBV and HCV among blood donors in Kosovo.

Authors:  Hajrullah Fejza; Skender Telaku
Journal:  Virol J       Date:  2009-02-13       Impact factor: 4.099

4.  Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.

Authors:  J E Yeon; W Yoo; S P Hong; Y J Chang; S K Yu; J H Kim; Y S Seo; H J Chung; M S Moon; S-O Kim; K S Byun; C H Lee
Journal:  Gut       Date:  2006-02-04       Impact factor: 23.059

Review 5.  Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

Authors:  Ilaria Lenci; Martina Milana; Giuseppe Grassi; Tommaso M Manzia; Carlo Gazia; Giuseppe Tisone; Roberta Angelico; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2020-05-14       Impact factor: 5.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.